Expands Award-Winning Compliance Platform to Include International Research Consortium’s Preclinical Study Standards

COMPLi® solution will support guidelines set forth by Enhancing Quality In Preclinical Data (EQIPD) to improve data integrity standards and accelerate novel drug development

SAN DIEGO--(), the healthcare industry’s leading marketplace for outsourced research, has partnered with Enhancing Quality In Preclinical Data (EQIPD) to help define and improve data quality within preclinical research. A self-certification questionnaire is now accessible via’s award-winning compliance solution COMPLi®, allowing global suppliers to self-certify prior to working with biopharma research organizations. With this self-certification, suppliers demonstrate their data integrity processes and procedures to potential clients.

“EQIPD’s holistic approach to tackling the challenges related to data quality within preclinical research aligns with our COMPLi standards, which provides researchers with the proper due diligence necessary to source from suppliers of preclinical services,” stated Matt McLoughlin, VP of Categories & Compliance. “We are working with EQIPD to ensure data integrity is at the heart of research.”

Currently, there are no globally accepted quality standards when it comes to reporting data generated by preclinical research. To define and implement such standards EQIPD has formed a consortium of key stakeholders that includes large pharma (including a number of current clients), biotech companies, academia and compliance solutions. The consortium works closely with Stakeholder Group members such as EQIPD is looking to develop best practices that can be shared across R&D in the life sciences.

“Use of the EQIPD-derived tools by stakeholders such as enables EQIPD to deliver its mission of improving data integrity standards across the global research community,” stated Anton Bespalov of PAASP, an EQIPD consortium member. “Their COMPLi platform can increase visibility to our work and ensure it aligns completely with the goals of EQIPD moving forward.”

“Including a self-certification questionnaire, based on the EQIPD standard, within COMPLi, streamlines and harmonises the data quality and data integrity due diligence process applied by biopharma research organizations during the on-boarding of preclinical service suppliers,” stated Sandrine Bongiovanni of Novartis Pharma AG.

Research organizations looking to self-certify or learn more about COMPLi can visit

About is the pharmaceutical industry’s leading AI-powered marketplace for outsourced R&D. The marketplace simplifies R&D sourcing, saves time and money, reduces risk, and provides access to the latest innovative tools and technologies. operates private enterprise marketplaces for most of the world’s major pharmaceutical companies, over 80 biotechnology companies, the Biotechnology Innovation Organization (BIO), and the US National Institutes of Health (NIH).

Join on social media: LinkedIn, Twitter, YouTube, Facebook, and Instagram


The Enhancing Quality in Preclinical Data consortium (EQIPD; previously "European Quality in Preclinical Data") was founded in 2017 by 29 academic institutions, pharmaceutical companies, and SMEs from 8 countries (

Supported through the European Union’s Innovative Medicines Initiative (IMI), major deliverables of the EQIPD consortium were the development of a novel preclinical research quality system that could be applied in both the public and private sectors, and the generation of online training capacity in good research practice.

The consortium works closely with a large group of associated collaborators, advisors and stakeholders drawn from nearly 100 organizations in Europe and the US and including research institutions, publishers, funders, learned societies and professional societies.

Follow EQIPD on social media:

Sean Preci, +1 858 455-1300 ext. 401
Director of Communications

Release Summary's award-winning COMPLi solution now supports preclinical data guidelines set forth by Enhancing Quality In Preclinical Data (EQIPD)

Sean Preci, +1 858 455-1300 ext. 401
Director of Communications